Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-29
2011-03-29
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S340000, C514S374000, C544S310000, C546S271400, C548S236000
Reexamination Certificate
active
07915270
ABSTRACT:
Certain oxazole ketone compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as MS).
REFERENCES:
patent: 6096784 (2000-08-01), Lerner et al.
patent: 6462054 (2002-10-01), Boger
patent: WO 96/09817 (1994-09-01), None
patent: WO 97/49667 (1996-06-01), None
patent: WO 99/26584 (1997-11-01), None
patent: WO 02/87569 (2001-04-01), None
patent: WO 2004/033652 (2004-04-01), None
Bundgaard, Design of Prodrugs: Introduction, p. 1, 1985.
Silverman, Prodrugs and Drug Delivery Systems, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400, 1992.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Damasio, Alzheimer's Disease and related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Seierstad et al., Discovery and Development of Fatty Acid Amide Hydrolase (FAAH) Inhibitors, Journal of Medicinal Chemistry, vol. 51, No. 23, pp. 7327-7343, 2008.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, pp. 1004-1010, 1996.
Gura, Systems for identifying New Drugs Are Often Faulty, Cancer Models, Science, vol. 278, No. 5340, pp. 1041-1042, Nov. 1997.
Johnson et al., Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials, British Journal of Cancer (2001) 64(10): 1424-1431.
Berge, et al., “Pharmaceutical Salts”,J. Pharm. Sci. 66: 1-19 (1977).
Devane, et al., “Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor”,Science 258: 1946-1949 (1992).
Cravatt, et al., “Chemical Characterization of a Family of Brain Lipids That Induce Sleep”,Science 268: 1506-1509 (1995).
Conde-Frieboes, et al., “Activated Ketones as Inhibitors of Intracellular Ca+2-Dependent and Ca+2-Independent Phospholipase A2”,J. Am. Chem. Soc. 118: 5519-5525 (1996).
Patterson, et al., “Inhibition of Oleamide Hydrolase Catalyzed Hydrolysis of the Endogenous Sleep-Inducing Lipidcis-9- Octadecenamide”,J. Am. Chem. Soc. 118: 5938-5945 (1996).
Cravatt, et al., “Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides”,Nature 384: 83-87 (1996).
Patricelli, et al., “An Endogenous Sleep-Inducing Compound is a Novel Competitive Inhibitor of Fatty Acid Amide Hydrolase”,Bioorg. Med. Chem. Lett. 8: 613-618 (1998).
Baker, et al., “Cannabinoids control spasticity and tremor in a multiple sclerosis model”,Nature 404: 84-87 (2000).
Boger, et al., “Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide”,Proc. Natl. Acad. Sci. USA 97: 5044-5049 (2000).
Baker, et al., “Endocannabinoids control spasticity in a multiple sclerosis model”,FASEB J. 15: 300-302 (2001).
Robson, et al., “Therapeutic aspects of cannabis and cannabinoids”,Br. J. Psychiatry 178: 107-115 (2001).
Mendelson, et al., “The Hypnotic Actions of the Fatty Acid Amide, Oleamide”,Neuropsychopharmacology 25: S36-S39 (2001).
Cravatt, et al., “Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase”,Proc. Natl. Acad. Sci. USA 98: 9371-9376 (2001).
Ueda, et al., “Purification and Characterization of an Acid Amidase Selective for N-Palmitoylethanolamine, a Putative Endogenous Anti-inflammatory Substance”,J. Biol. Chem. 276: 35552-35557 (2001).
Jefferis, et al., “Target neuron prespecification in the olfactory map of Drosophila”,Nature 414: 204-208 (2001).
Kirkham, et al., “Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol”,Br. J. Pharmacol. 136: 550-557 (2002).
Lambert, et al., “The Palmitoylethanolamide Family: A New Class of Anti-Inflammatory Agents”,Curr. Med. Chem. 9: 663-674 (2002).
Kathuria, et al., “Modulation of anxiety through blockade of anandamide hydrolysis”,Nature Med. 9: 76-81 (2003).
Piomelli, D., “The Molecular Logic of Endocannabinoid Signalling”,Nature Rev. 4: 873-884 (2003).
Svendsen, et al., “Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial”,Br. Med. J. 329: 253-260 (2004) [BMJ, doi:10.1136/bmj.38149.566979.AE].
Boger, et al., “Discovery of a Potent, Selective, and Efficacious Class of Reversible α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Effective as Analgesics”,J. Med. Chem. 48: 1849-1856 (2005).
Rao Deepak
Schwegman Lundberg & Woessner, P.A.
The Scripps Research Institute
LandOfFree
Oxazole ketones as modulators of fatty acid amide hydrolase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxazole ketones as modulators of fatty acid amide hydrolase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxazole ketones as modulators of fatty acid amide hydrolase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2642789